Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Surveillance in Japan on Long Term Drug Use of TRADIANCE Combination Tablets AP and BP in Patients With Type 2 Diabetes Mellitus

Next Previous
Trial Profile

Post Marketing Surveillance in Japan on Long Term Drug Use of TRADIANCE Combination Tablets AP and BP in Patients With Type 2 Diabetes Mellitus

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin/linagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 28 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 11 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top